Anzeige
Meldung des Tages: Waffenarsenal schrumpft: Startet hier der nächste strategische Rohstoff-Run?

Addex Therapeutics News

Aktie
WKN:  A0MSH6 ISIN:  CH0029850754 US-Symbol:  ADDXF Branche:  Biotechnologie Land:  Schweiz
0,0368 CHF
-0,0012 CHF
-3,16%
0,0404 € 15:22:56 Uhr
Depot/Watchlist
Marktkapitalisierung *
5,90 Mio. €
Streubesitz
92,80%
KGV
0,79
Index-Zuordnung
-

Addex Therapeutics News

03.02.26 - GlobeNewswire
Addex Announces Publication of Preclinical Data Supporting Potential of mGlu7 Negative Allosteric Modulators to Transform Anxiety and Fear-Related Disorder Treatment
Data published in Molecular Psychiatry
07.01.26 - GlobeNewswire
Addex Spin-Out Neurosterix has started a Phase 1 Clinical Study with M4 PAM - NTX-253 for Schizophrenia
Ad Hoc Announcement Pursuant to Art. 53 LR
11.12.25 - GlobeNewswire
Addex Amends its at the Market Offering Agreement With H.C. Wainwright & Co.
Ad Hoc Announcement Pursuant to Art. 53 LR
04.12.25 - GlobeNewswire
Addex Therapeutics Reports 2025 Third Quarter Financial Results and Provides Corporate Update
Ad Hoc Announcement Pursuant to Art. 53 LR
01.12.25 - GlobeNewswire
Addex Therapeutics to Report 2025 Third Quarter Financial Results And Host Conference Call on December 4, 2025
Geneva, Switzerland, December 1, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-​stage biopharmaceutical company focused on developing a portfolio of novel ...
29.10.25 - GlobeNewswire
Addex Increases Issued Share Capital to Create Treasury Shares
Ad Hoc Announcement Pursuant to Art. 53 LR
30.09.25 - GlobeNewswire
Addex Therapeutics Reports 2025 Half Year and Second Quarter Financial Results and Provides Corporate Update
Cash position of CHF 2.3 million at end of H1 2025 GABAB PAM chronic cough candidate demonstrated robust anti-​tussive activity in disease models Regained rights to phase 2 ...
26.09.25 - GlobeNewswire
Addex Therapeutics to Report 2025 Half-year and Second Quarter Financial Results on September 30, 2025 and Host Conference Call on October 1, 2025
Geneva, Switzerland, September 26, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-​stage biopharmaceutical company focused on developing a portfolio of novel small ...
23.09.25 - GlobeNewswire
Addex Appoints Bank of New York Mellon as Depositary Bank
Ad Hoc Announcement Pursuant to Art. 53 LR
30.06.25 - GlobeNewswire
Addex Leads CHF 2 Million Investment in Stalicla to Advance Precision Medicine in Neuropsychiatric Disorders
Ad Hoc Announcement Pursuant to Art. 53 LR
25.06.25 - GlobeNewswire
Addex Shareholders Approve All Resolutions at Annual General Meeting
Ad Hoc Announcement Pursuant to Art. 53 LR
19.06.25 - GlobeNewswire
Addex Therapeutics Reports Q1 2025 Financial Results and Provides Corporate Update
Strong cash position of CHF2.8 million at end of Q1 2025 GABAB PAM chronic cough candidate demonstrated robust anti-​tussive activity in disease models Regained rights to our ...
18.06.25 - GlobeNewswire
Addex Therapeutics to Release Q1 2025 Financial Results and Host Conference Call on June 19, 2025
Geneva, Switzerland, June 18, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-​stage biopharmaceutical company focused on developing a portfolio of novel small ...
06.06.25 - GlobeNewswire
Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Multiple Chronic Cough Preclinical Models
Ad Hoc Announcement Pursuant to Art. 53 LR
05.06.25 - GlobeNewswire
Addex to Present Positive GABAB PAM Chronic Cough Data at the 10th American Cough Conference 
Geneva, Switzerland, June 5, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-​stage biopharmaceutical company focused on developing a portfolio of novel small ...
03.06.25 - GlobeNewswire
Addex Convenes Annual General Meeting 2025
Geneva, Switzerland, June 3, 2025 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-​stage biopharmaceutical company focused on developing a portfolio of novel ...
12.05.25 - GlobeNewswire
Addex Partner Indivior Advances GABAB Positive Allosteric Modulator Program Successfully Through IND Enabling Studies
Ad Hoc Announcement Pursuant to Art. 53 LR
30.04.25 - GlobeNewswire
Addex Enters Option Agreement with Sinntaxis for an Exclusive License to Intellectual Property Covering the Use of mGlu5 Inhibitors in Brain Injury Recovery
Ad Hoc Announcement Pursuant to Art. 53 LR
25.04.25 - GlobeNewswire
Addex Reports Full Year 2024 Financial Results and Provides Corporate Update
Launched Neurosterix with Perceptive Advisors, raising USD 65 million in Series A to advance preclinical portfolio Indivior selected GABAB PAM drug candidate and started IND ...
24.04.25 - GlobeNewswire
Addex Therapeutics to Release Full-Year 2024 Financial Results and Host Conference Call on April 25, 2025
Geneva, Switzerland, April 24, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-​stage biopharmaceutical company focused on developing a portfolio of novel small ...

Newssuche

Videos

newspaper
19.03.26
COUNTER HUNTER Strategie Einführung
Live-​Seminar am 29.3. ab 14 Uhr! Wie immer wird die Schulung auch aufgezeichnet und allen ... Mehr »